drugset
drugset / Trial / NCT06008366

A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors

NCT06008366 ↗

Phase 1/2 Unknown 281 enrolled Mabwell (Shanghai) Bioscience Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

7MW3711 is an antibody-drug conjugate(ADC) directed to a target wildly expressed on solid tumors. This is an open-label, multicenter, phase 1/2 study to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 7MW3711 in subjects with advanced solid tumors.

Timeline

Start
2023-09-05
Primary completion
2025-08-30
Completion
2026-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject 7MW3711 Other / unclassified — Intravenous

Indications

neoplasm